Peptides, Vol. 1. Copyright © by ANKHO International Inc. Printed in the U.S.A.

PEPTIDES

VOLUME 1 1980

SUBJECT INDEX

Acid secretion
  bethanechol, 217
  bombesin, 217
  bombesin nonapeptide, 217
  cholinergic peptidergic neurohormonal transmission, 217
  2-deoxyglucose, 217
  fundic vagotomy, 217
  gastrin, 217
Acromegaly
  half-life, 257
  hepatic failure, 257
  radioimmunoassay, 257
  somatostatin, 257
Acrophase
  $ACTH_{1-17}$, 387
  circadian, 387
  cosinor analysis, 387
  rheumatoid arthritis, 387
  urinary free cortisol, 387
ACTH
  adrenal cortex, 249
  aging, 55
  attention, 55, 277
  axon length, 135
  body temperature, 15
  central peptides, 15
  cognition, 55
  crush denervation, 135
  direct interaction of peptide regulators and target cell nuclei, 249
  endorphin, 223
  glucagon, 15
  guinea pig, 223
  human, 55
  immunocytochemistry, s3, s11
  immunohistochemistry, 249
  learning, 277
  motor endplates, 135
  motor function, 135
  MSH, 55, 277
  α-MSH, 15
  muscle fibers, 135
  neuroanatomy, s3, s11
  neuropeptides, s3
  opiate peptides, s11
  oxytocin, 15
  peptide, 55, 277
  prolactin, 249
  protein synthesis, 135
  regeneration, 135
  sensation, 135
  steroidogenesis, 223
  vasopressin, 15
  visual retention, 55
$ACTH_{1-17}$
  acrophase, 387
  circadian, 387
  cosinor analysis, 387
  rheumatoid arthritis, 387
  urinary free cortisol, 387
$ACTH_{4-10}$
  conditioned taste aversion, 207
  plasma corticosterone, 207
$ACTH/MSH_{4-9}$ analog
  awareness enhancement, 109
  mental retardation, 109
Activity
  analgesia, 365
  drinking, 383
  dynorphin, 365
  eating, 383
  endorphin, 365
  enkephalin, 365
  gastrin, 383
  hormones, 365
  learning, 365
  localization, 365
  memory, 365
  motilin, 383
  neurotransmitters, 365
  receptors, 365
  schizophrenia, 365
  tolerance, 365
  vasoactive intestinal polypeptide, 383
Adrenal cortex
  ACTH, 249
  direct interaction of peptide regulators and target cell nuclei, 249
  immunohistochemistry, 249
  prolactin, 249
Adrenal medulla
  functional brain transplants, s101
Aggression
  α-MSH, 69
  olfaction, 69
  preputial gland, 69
Aging
  ACTH, 55
  attention, 55
  baroregulation, s159
  brain, s185
  cognition, 55
  dopamine, s135
  endocrine systems, s185
  human, 55
  hypophysial secretion, s135
  hypothalamus, s135, s239
  immunocytochemistry, s239

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Aging (continued)
memory, s197
monoamines, s141
MSH, 55
neurohypophyseal function, s159
neuronal interactions, s141
neuropeptides, s141
neurophysin, s239
opiate receptors, s197
osmoregulation, s159
ovarian-hypothalamic-pituitary interaction, s163
oxytocin, s239
peptide, 55
prolactin, s135
reproduction, s163
supraoptic nucleus, s141
theoretical implications, s185
vasopressin, s159, s239
visual retention, 55
Aging effects
hypothalamic ovary, s69
melatonin, s69
pineal gland, s69
reproductive gonadotrophins, s69
Akinesia
γ-aminobutyric acid, 139
analgesia, 139
D-Ala²-Met-enkephalinamide, 139
taurine, 139
Alpha-methyl tyrosine
3-fluoro-tyrosine, 175
Met-enkephalin, 175
3-methyl-tyrosine, 175
opiates, 175
peptide, 175
tetrafluorotyrosine, 175
tyrosine-modified analogs, 175
vas deferens, 175
Ambient temperature
amphetamine, 243
chlorpromazine, 243
drug interaction, 243
locomotion, 243
MIF-I, 243
ᵃ-MSH, 243
thermoregulation, 243
γ-Aminobutyric acid
akinesia, 139
analgesia, 139
D-Ala²-Met-enkephalinamide, 139
taurine, 139
α-Aminoisobutyric acid
bradykinin analogs, 231
Aminopeptidase metabolism of enkephalin
enkephalin degradation, 31
enkephalinase and angiotensin converting enzyme, 31
enkephalinase inhibitors, 31
enkephalinase properties, 31
Amphetamine
ambient temperature, 243
chlorpromazine, 243
drug interaction, 179, 243
β-endorphin, 179
hypothermia, 179
locomotion, 243
MIF-I, 243
morphine, 179
motor activity, 179
α-MSH, 243
naloxone, 179
peptide, 179
thermoregulation, 243
Analgesia
activity, 365
akinesia, 139
γ-aminobutyric acid, 139
dynorphin, 341, 365
eating, 341
endorphin, 365
enkephalin, 365
D-Ala²-Met-enkephatinamide, 139
grooming, 341
guinea pig ileum, 293
hormones, 365
learning, 365
localization, 365
memory, 365
MIF-I, 293
morphine, 293
motor activity, 293
mouse vas deferens, 293
naloxone, 341
neurotransmitters, 365
opiate receptors, 293
opioid, 341
rearing, 341
receptors, 365
schizophrenia, 365
taurine, 139
tolerance, 365
Anatomical distribution
Met-enkephalin, 211
Met-enkephalin sulphoxide, 211
invertebrates, 211
phylogenetic distribution, 211
radioimmunoassay, 211
vertebrates, 211
Anatomy
brain, 23
β-endorphin, 23
enkephalin, 23
immunocytochemistry, 23
α-MSH, 23
noradrenaline, 23
Androgenized females
anovulatory syndrome, s85
hypothalamic-pituitary axis, s85
LHRH, s85
Anovulatory syndrome
androgenized females, s85
hypothalamic-pituitary axis, s85
LHRH, s85
Antagonists
chemotaxis, 289
formyl-Met-Leu-Phe-OH, 289
rabbit neutrophils, 289
rapid mixed anhydride coupling, 289
Anterior hypothalamus
hypothermia, 333
neurotensin, 333
periaqueductal gray, 333
preoptic area, 333
Aortic arch afferents
baroreceptors, 1
chemoreceptors, 1
nucleus tractus solitarius, 1
substance P, 1
vagal afferents, 1

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Aortic nerve
baroreceptors, 359
chemoreceptors, 359
nodose ganglia, 359
retrograde transport, 359
substance P, 359
'true blue', 359
Attention
ACTH, 55, 277
aging, 55
cognition, 55
human, 55
learning, 277
MSH, 55, 277
peptide, 55, 277
visual retention, 55
Autonomic ganglia
arrest and migration of cerebellar neurons, s221
chemotactic factors, s221
neural transplantation, s221
neurotropism, s221
Autoradiography
development of somatostatin neurons, s79
Awareness enhancement
ACTH/MSH$_{4-9}$ analog, 109
mental retardation, 109
Axon length
ACTH, 135
crush denervation, 135
motor endplates, 135
motor function, 135
muscle fibers, 135
protein synthesis, 135
regeneration, 135
sensation, 135
Axosomatic synapses
hypothalamus, 37
immunocytochemistry, 37
LHRH, 37
ultrastructural cytology, 37

Baroreceptors
aortic arch afferents, 1
aortic nerve, 359
chemoreceptors, 1, 359
nodose ganglia, 359
nucleus tractus solitarius, 1
retrograde transport, 359
substance P, 1, 359
'true blue', 359
vagal afferents, 1
Baroregulation
aging, s159
neurohypophyseal function, s159
Behavioral sequence of satiety
bombesin, 131
eating, 131
gastric cannula, 131
satiety, 131
sham feeding, 131
Bethanechol
acid secretion, 217
bombesin, 217
bombesin nonapeptide, 217
cholinergic peptidergic neurohormonal transmissions, 217
2-deoxyglucose, 217
fundic vagotomy, 217
gastrin, 217
Birth
brain, 125
α-MSH, 125
pituitary, 125
plasma, 125
sexual maturity, 125
Blood-brain barrier
bombesin, 347
cholecystokinin, 347
CSF, 347
peptide, 347
relationship, 347
Body temperature
ACTH, 15
central peptides, 15
glucagon, 15
α-MSH, 15
oxytocin, 15
vasopressin, 15
Bombesin
acid secretion, 217
behavioral sequence of satiety, 131
bethanechol, 217
blood-brain barrier, 347
bombesin nonapeptide, 217
cholecystokinin, 347
cholesterol, 381
cholinergic peptidergic neurohormonal transmission, 217
CSF, 347
2-deoxyglucose, 217
eating, 131
fundic vagotomy, 217
gastric cannula, 131
gastrin, 217
neurotensin, 381
peptide, 347
relationship, 347
satiety, 131
sham feeding, 131
somatostatin, 381
substance P, 381
Bombesin nonapeptide
acid secretion, 217
bethanechol, 217
bombesin, 217
cholinergic peptidergic neurohormonal transmission, 217
2-deoxyglucose, 217
fundic vagotomy, 217
gastrin, 217
bPTH$_{1-34}$
bradykinin, 285
corticotropin inhibiting peptide, 285
duration of action, 285
effectiveness, 285
eledoisin, 285
neurotensin, 285
potency, 285
substance P, 285
vasoactive intestinal peptide, 285
xenopsin, 285
Bradykinin
bPTH$_{1-34}$, 285
corticotropin inhibiting peptide, 285
duration of action, 285
effectiveness, 285
eledoisin, 285
FSH, 201
GH, 201
LH, 201

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Bradykinin (continued)
neurotensin, 285
potency, 285
prolactin, 201
substance P, 285
TSH, 201
vasoactive intestinal peptide, 285
xenopsin, 285
Bradykinin analogs
α-aminoisobutyric acid, 231
Brain
aging, s185
anatomy, 23
anterior hypothalamus, 333
birth, 125
caudate nucleus, s111
cerebellum, s221
dorsal raphe nucleus, s101
endocrine systems, s185
β-endorphin, 23
enkephalin, 23
hypothalamic-pituitary axis, s85
hypothalamus, s27, 37, 47, s117, s125, s135, s163, s211, s239, 301
immunocytochemistry, 23
median eminence, 59, s85, 97
α-MSH, 23, 125
neostriatum, s111
neurohypophysis, s45
nigro-striatal system, s177
noradrenaline, 23
nucleus tractus solitarius, 1
organum vasculosum, s85
organum vasculosum lamina terminalis, 97
paraventricular nucleus, 77, 315
periaqueductal gray, 333
pineal gland, s69, 281
pituitary, 19, 125, s163, 309
plasma, 125
preoptic area, 333
sexual maturity, 125
substantia nigra, s101, s111
supraoptic nucleus, s27, s51, 77, s141, s229, 315
theoretical implications, s185
Brain development
vasopressin, s203

Catalepsy
FLA-63, 103
haloperidol, 103
locomotor activity, 103
α-methylparatyrosine, 103
muscular rigidity, 103
neuropeptides, 103
phenoxybenzamine, 103
substance P, 103
Catecholamines
histofluorescence, 77
immunocytochemistry, 77
neurophysin, 77
ontogeny, 77
paraventricular nucleus, 77
supraoptic nucleus, 77
vasopressin, 77
Caudate nucleus
functional reinnervation, s111
nigral transplants, s111
Cell culture
hypothalamus, s211
immunocytochemistry, s211
neuronal cell markers, s211
Central peptides
ACTH, 15
body temperature, 15
glucagon, 15
α-MSH, 15
oxytocin, 15
vasopressin, 15
Cerebellar neurons
arrest and migration, s221
autonomic ganglia, s221
chemotactic factors, s221
neural transplantation, s221
neurotrophism, s221
Cerebral ventricular injections
cholecystokinin-octapeptide, 51
cumulative daily feed intake, 51
eating, 51
meal size, 51
sheep, 51
Chemoreceptors
aortic arch afferents, 1
aortic nerve, 359
baroreceptors, 1, 359
nodose ganglia, 359
nucleus tractus solitarius, 1
retrograde transport, 359
substance P, 1, 359
'true blue', 359
vagal afferents, 1
Chemotactic factors
arrest and migration of cerebellar neurons, s221
autonomic ganglia, s221
neural transplantation, s211
neurotrophism, s211
Chemotaxis
antagonists, 289
formyl-Met-heu-Phe-OH, 289
rabbit neutrophils, 289
rapid mixed anhydride coupling, 289
Chlorpromazine
ambient temperature, 243
amphetamine, 243
drug interaction, 243
locomotion, 243
MIF-I, 243
α-MSH, 243
thermoregulation, 243
Cholecystokinin
blood-brain barrier, 347
bombesin, 347
CSF, 347
eating, 47
hypothalamic feeding, 47
noradrenergic feeding "circuit", 47
norepinephrine, 47
peptide, 347
relationship, 347
satiety mechanism, 47
Cholecystokinin-octapeptide
cerebral ventricular injections, 51
cumulative daily feed intake, 51
eating, 51
meal size, 51
sheep, 51
Cholesterol
bombesin, 381
neurotensin, 381

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

somatostatin, 381
substance P, 381
Cholinergic peptidergic neurohormonal transmission
acid secretion, 217
bethanechol, 217
bombesin, 217
bombesin nonapeptide, 217
2-deoxyglucose, 217
fundic vagotomy, 217
gastrin, 217
Circadian
$ACTH_{1-17}$, 387
acrophase, 387
cosinor analysis, 387
rheumatoid arthritis, 387
urinary free cortisol, 387
Cognition
ACTH, 55
aging, 55
attention, 55
human, 55
MSH, 55
peptide, 55
visual retention, 55
Conditioned taste aversion
$ACTH_{4-10}$, 207
plasma corticosterone, 207
Congenital deficiency
immunocytochemistry, 11
neural grafts, 11
neurophysin, 11
vasopressin, 11
Corticotropin inhibiting peptide
$bPTH_{1-34}$, 285
bradykinin, 285
duration of action, 285
effectiveness, 285
eledoisin, 285
neurotensin, 285
potency, 285
substance P, 285
vasoactive intestinal peptide, 285
xenopsin, 285
Cosinor analysis
acrophase, 387
$ACTH_{1-17}$, 387
circadian, 387
rheumatoid arthritis, 387
urinary free cortisol, 387
Crush denervation
ACTH, 135
axon length, 135
motor endplates, 135
motor function, 135
muscle fibers, 135
protein synthesis, 135
regeneration, 135
sensation, 135
CSF
blood-brain barrier, 347
bombesin, 347
cholecystokinin, 347
peptide, 347
relationship, 347
Cumulative daily feed intake
cerebral ventricular injections, 51
cholecystokinin-octapeptide, 51
eating, 51
meal size, 51
sheep, 51
Cytodifferentiation
supraoptic nucleus, s51

Defecation
emotionality, 147
11-hydroxycorticosterone, 147
hypophysectomy, 147
melatonin, 147
memory, 147
α-MSH, 147
passive avoidance, 147
2-Deoxyglucose
acid secretion, 217
bethanechol, 217
bombesin, 217
bombesin nonapeptide, 217
cholinergic peptidergic
neurohormonal transmission, 217
fundic vagotomy, 217
gastrin, 217
Development
extrahypothalamic innervation, 315
fetus, 315
hormonal effects on transplanted embryonic hypothalamus, s117
immunocytochemistry, 315
oxytocin, 315
paraventricular nucleus, 315
somatostatin neurons, s79
supraoptic nucleus, 315
vasopressin, 315
Direct interaction of peptide regulators and target cell nuclei
ACTH, 249
adrenal cortex, 249
immunohistochemistry, 249
prolactin, 249
Distribution
endocrine, 159
immunochemistry, 159
neurotensin, 159
peptide, 159
radioimmunoassay, 159
Dopamine
aging, s135
gonadotropin-releasing hormone, 59
hypophysial secretion, s135
hypothalamus, s135
median eminence, 59
prolactin, s135
simultaneous histofluorescence-immunocytochemistry, 59
Dorsal raphe nucleus
functional brain transplants, s101
Drinking
activity, 383
dynorphin, 353
eating, 383
[D-Ala^2,F_5Phe^4]-Met-enkephalin-NH_2, 353
[D-Phe^4]-Met-enkephalin, 353
gastrin, 383
incentive motivation, 353
MIF-I, 353
motilin, 383
naloxone, 353
vasoactive intestinal polypeptide, 383

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Drug
amphetamine, 179, 243
bethanechol, 217
chlorpromazine, 243
2-deoxyglucose, 217
dynorphin, s11, 341, 353, 365
D-Ala²-Met-enkephalinamide, 139
FLA-63, 103
haloperidol, 103
6-hydroxydopamine, s111
α-methylparatyrosine, 103
morphine, 179, 237, 293
naloxone, 73, 179, s197, 237, 341, 353
naltrexone, 309
phenoxybenzamine, 103
Drug interaction
ambient temperature, 243
amphetamine, 179, 243
chlorpromazine, 243
β-endorphin, 179
hypothermia, 179
locomotion, 243
MIF-I, 243
morphine, 179
motor activity, 179
α-MSH, 243
naloxone, 179
peptide, 179
thermoregulation, 243
Duodenal pH
pancreatic diversion, 155
pancreatic secretion, 155
secretin, 155
Duration of action
$bPTH_{1-34}$, 285
bradykinin, 285
corticotropin inhibiting peptide, 285
effectiveness, 285
eledoisin, 285
neurotensin, 285
potency, 285
substance P, 285
vasoactive intestinal peptide, 285
xenopsin, 285
Dynorphin
activity, 365
analgesia, 341, 365
drinking, 353
eating, 341
endorphin, 365
enkephalin, 365
[D-Ala², F_5Phe⁴]-Met-enkephalin-NH_2, 353
[D-Phe⁴]-Met-enkephalin, 353
grooming, 341
hormones, 365
immunocytochemistry, s11
incentive motivation, 353
learning, 365
localization, 365
memory, 365
MIF-I, 353
naloxone, 341, 353
neuroanatomy, s11
neurotransmitters, 365
opiate peptides, s11
opioid, 341
rearing, 341
receptors, 365
schizophrenia, 365
tolerance, 365
Eating
activity, 383
analgesia, 341
behavioral sequence of satiety, 131
bombesin, 131
cerebral ventricular injections, 51
cholecystokinin, 47
cholecystokinin-octapeptide, 51
cumulative daily feed intake, 51
drinking, 383
dynorphin, 341
gastric cannula, 131
gastrin, 383
grooming, 341
hypothalamic feeding, 47
meal size, 51
motilin, 383
naloxone, 341
noradrenergic feeding "circuit", 47
norepinephrine, 47
rearing, 341
satiety, 131
satiety mechanism, 47
sham feeding, 131
sheep, 51
vasoactive intestinal polypeptide, 383
Effectiveness
$bPTH_{1-34}$, 285
bradykinin, 285
corticotropin inhibiting peptide, 285
duration of action, 285
eledoisin, 285
neurotensin, 285
potency, 285
substance P, 285
vasoactive intestinal peptide, 285
xenopsin, 285
Eledoisin
$bPTH_{1-34}$, 285
bradykinin, 285
corticotropin inhibiting peptide, 285
duration of action, 285
effectiveness, 285
neurotensin, 285
potency, 285
substance P, 285
vasoactive intestinal peptide, 285
xenopsin, 285
Emotionality
defecation, 147
11-hydroxycorticosterone, 147
hypophysectomy, 147
melatonin, 147
memory, 147
α-MSH, 147
passive avoidance, 147
Endocrine
distribution, 159
immunochemistry, 159
intestinal, 167
neurotensin, 159, 167
peptide, 159, 167
radioimmunoassay, 159, 167
sequence, 167
Endocrine systems
aging, s185
brain, s185
theoretical implications, s185
Endorphin
ACTH, 223

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

activity, 365
analgesia, 365
dynorphin, 365
enkephalin, 365
guinea pig, 223
hormones, 365
learning, 365
localization, 365
memory, 365
neurotransmitters, 365
receptors, 365
schizophrenia, 365
steroidogenesis, 223
tolerance, 365
β-Endorphin
d-amphetamine, 179
anatomy, 23
brain, 23
drug interaction, 179
enkephalin, 23
hypothermia, 179
immunocytochemistry, s3, s11, 23
insulin, 309
morphine, 179
motor activity, 179
α-MSH, 23
naloxone, 179
naltrexone, 309
neuroanatomy, s3, s11
neuropeptides, s3
noradrenaline, 23
obesity, 309
opiate peptides, s11, 309
pancreatic islets, 309
peptide, 179
pituitary, 309
Enkephalin
activity, 365
anatomy, 23
analgesia, 365
brain, 23
dynorphin, 365
endorphin, 365
β-endorphin, 23
hormones, 365
immunocytochemistry, 23
learning, 365
localization, 365
melatonin, 73
memory, 365
morphine, 237
MSH, 73
α-MSH, 23
naloxone, 73, 237
neurotransmitters, 365
noradrenaline, 23
pupil mydriasis, 237
receptors, 365
schizophrenia, 365
tolerance, 365
xanthophore aggregation, 73
[D-Ala^2,F$_5$Phe^4]-Met-Enkephalin-NH$_2$
drinking, 353
dynorphin, 353
[D-Phe^4]-Met-enkephalin, 353
incentive motivation, 353
MIF-I, 353
naloxone, 353
[D-Phe^4]-Met-Enkephalin
drinking, 353
dynorphin, 353
[D-Ala^2,F$_5$Phe^4]-Met-enkephalin-NH$_2$, 353
incentive motivation, 353
MIF-I, 353
naloxone, 353
Enkephalin degradation
aminopeptidase metabolism of enkephalin, 31
enkephalinase and angiotensin converting enzyme, 31
enkephalinase inhibitors, 31
enkephalinase properties, 31
D-Ala^2-Met-Enkephalinamide
akinesia, 139
γ-aminobutyric acid, 139
analgesia, 139
taurine, 139
Met-Enkephalin
alpha-methyl-tyrosine, 175
anatomical distribution, 211
Met-enkephalin sulphoxide, 211
3-fluoro-tyrosine, 175
invertebrates, 211
3-methyl-tyrosine, 175
opiates, 175
peptide, 175
phylogenetic distribution, 211
radioimmunoassay, 211
tetrafluorotyrosine, 175
tyrosine-modified analogs, 175
vas deferens, 175
vertebrates, 211
Met-Enkephalin sulphoxide
anatomical distribution, 211
Met-enkephalin, 211
invertebrates, 211
phylogenetic distribution, 211
radioimmunoassay, 211
vertebrates, 211
Enkephalinase and angiotensin converting enzyme
aminopeptidase metabolism of enkephalin, 31
enkephalin degradation, 31
enkephalinase inhibitors, 31
enkephalinase properties, 31
Enkephalinase inhibitors
aminopeptidase metabolism of enkephalin, 31
enkephalin degradation, 31
enkephalinase and angiotensin converting enzyme, 31
enkephalinase properties, 31
Enkephalinase properties
aminopeptidase metabolism of enkephalin, 31
enkephalin degradation, 31
enkephalinase and angiotensin converting enzyme, 31
enkephalinase inhibitors, 31
Estrogen
hormonal effects, s117
hypothalamus, 301
LHRH, 301
subcellular LHRH particles, 301
sucrose density gradient fractionation, 301
transplanted embryonic hypothalamus, s117
Exophthalmia
Harderian gland, 19
light, 19
α-MSH, 19
photoperiod, 19
photoreceptor, 19
pituitary, 19
retina, 19
Extrahypothalamic innervation
development, 315
fetus, 315

Extrahypothalamic innervation (continued)
immunocytochemistry, 315
oxytocin, 315
paraventricular nucleus, 315
supraoptic nucleus, 315
vasopressin, 315

Fetal development
neurohypophysis, s45
neurophysins, s45
oxytocin, s45
vasopressin, s45
Fetus
development, 315
extrahypothalamic innervation, 315
immunocytochemistry, 315
oxytocin, 315
paraventricular nucleus, 315
supraoptic nucleus, 315
vasopressin, 315
FLA-63
catalepsy, 103
haloperidol, 103
locomotor activity, 103
α-methylparatyrosine, 103
muscular rigidity, 103
neuropeptides, 103
phenoxybenzamine, 103
substance P, 103
3-Fluoro-tyrosine
alpha-methyl-tyrosine, 175
Met-enkephalin, 175
3-methyl-tyrosine, 175
opiates, 175
peptide, 175
tetrafluorotyrosine, 175
tyrosine-modified analogs, 175
vas deferens, 175
Formyl-Met-Leu-Phe-OH
antagonists, 289
chemotaxis, 289
rabbit neutrophils, 289
rapid mixed anhydride coupling, 289
FSH
bradykinin, 201
GH, 201
LH, 201
prolactin, 201
TSH, 201
Functional aging
nigrostriatal system, s177
Functional brain transplants
adrenal medulla, s101
dorsal raphe nucleus, s101
substantia nigra, s101
Functional development
peptidergic neurons, s125
transplants, s125
Functional reinnervation
caudate nucleus, s111
6-hydroxydopamine, s111
nigral transplants, s111
regeneration, s111
substantia nigra, s111
Fundic vagotomy
acid secretion, 217
bethanechol, 217
bombesin, 217
bombesin norapeptide, 217
cholinergic peptidergic neurohormonal transmission, 217
2-deoxyglucose, 217
gastrin, 217

Gastric cannula
behavioral sequence of satiety, 131
bombesin, 131
eating, 131
satiety, 131
sham feeding, 131
Gastrin
acid secretion, 217
activity, 383
bethanechol, 217
bombesin, 217
bombesin nonapeptide, 217
cholinergic peptidergic neurohormonal transmission, 217
2-deoxyglucose, 217
drinking, 383
eating, 383
fundic vagotomy, 217
motilin, 383
vasoactive intestinal polypeptide, 383
GH
bradykinin, 201
FSH, 201
LH, 201
prolactin, 201
TSH, 201
Glucagon
ACTH, 15
body temperature, 15
central peptides, 15
α-MSH, 15
oxytocin, 15
vasopressin, 15
Gonadotropin-releasing hormone
dopamine, 59
median eminence, 59
simultaneous histofluorescence-immunocytochemistry, 59
Grooming
analgesia, 341
dynorphin, 341
eating, 341
naloxone, 341
opioid, 341
rearing, 341
Guinea pig
ACTH, 223
endorphin, 223
steroidogenesis, 223
Guinea pig ileum
analgesia, 293
MIF-I, 293
morphine, 293
motor activity, 293
mouse vas deferens, 293
opiate receptors, 293

Half-life
acromegaly, 257
hepatic failure, 257
radioimmunoassay, 257
somatostatin, 257

Haloperidol
catalepsy, 103
FLA-63, 103
locomotor activity, 103
α-methylparatyrosine, 103
muscular rigidity, 103
neuropeptides, 103
phenoxybenzamine, 103
substance P, 103
Harderian gland
exophthalmia, 19
light, 19
α-MSH, 19
photoperiod, 19
photoreceptor, 19
pituitary, 19
retina, 19
Hepatic failure
acromegaly, 257
half-life, 257
radioimmunoassay, 257
somatostatin, 257
Histofluorescence
catecholamines, 77
immunocytochemistry, 77
neurophysin, 77
ontogeny, 77
paraventricular nucleus, 77
supraoptic nucleus, 77
vasopressin, 77
Hormonal effects
development of embryonic hypothalamus, s117
Hormone
ACTH, s3, s11, 15, 55, 109, 135, 223, 249, 277
$ACTH^{1-17}$, 387
$ACTH_{4-10}$, 207
bombesin, 131, 217, 347, 381
bradykinin, 201, 231, 285
cholecystokinin, 47, 51, 347
corticosterone, 207
cortisol, 387
estradiol, s163
estrogen, s117, 301
FSH, 201
gastrin, 217
glucagon, 15
gonadotropin-releasing hormone, 59
11-hydroxycorticosterone, 147
insulin, 309
LH, s163, 201
LHRH, 37, 97, 301
melatonin, s69, 73, 147, 281
MIF-I, 243, 293, 353
MSH, s11, 15, 19, 23, 55, 69, 73, 109, 125, 147, 243, 277
neurophysin, s3, s11, 27, s45, s51, 77, s117, s239
neurotensin, 159, 167, 285, 333, 381
oxytocin, s3, 15, s45, s51, s239, 315
progesterone, s163
prolactin, s135, 201, 249, 325
secretin, 155
somatostatin, s79, 257, 381
TSH, 201
vasopressin, s3, 11, 15, s45, s51, 77, s125, s159, s203, s239, 261, 315
vasotocin, 281
Hormones
activity, 365
analgesia, 365
dynorphin, 365
endorphin, 365
enkephalin, 365
learning, 365
localization, 365
memory, 365
neurotransmitters, 365
receptors, 365
schizophrenia, 365
tolerance, 365
Human
ACTH, 55
aging, 55
attention, 55
cognition, 55
MSH, 55
peptide, 55
visual retention, 55
11-Hydroxycorticosterone
defecation, 147
emotionality, 147
hypophysectomy, 147
melatonin, 147
memory, 147
α-MSH, 147
passive avoidance, 147
6-Hydroxydopamine
functional reinnervation, s111
nigral transplants, s111
Hypophysectomy
defecation, 147
emotionality, 147
11-hydroxycorticosterone, 147
melatonin, 147
memory, 147
α-MSH, 147
passive avoidance, 147
Hypophysial secretion
aging, s135
dopamine, s135
hypothalamus, s135
prolactin, s135
Hypothalamic feeding
cholecystokinin, 47
eating, 47
noradrenergic feeding "circuit", 47
norepinephrine, 47
satiety mechanism, 47
Hypothalamic ovary
aging effects, s69
melatonin, s69
pineal gland, s69
reproductive gonadotrophins, s69
Hypothalamic-pituitary axis
androgenized females, s85
anovulatory syndrome, s85
LHRH, s85
Hypothalamus
aging, s135, s239
axosomatic synapses, 37
cell cultures, s211
dopamine, s135
estrogen, 301
hypophysial secretion, s135
immunocytochemistry, 37, s211, s239
LHRH, 37, 301
neuronal cell markers, s211
neurophysin, s27, s239
ontogeny, s27
oxytocin, s239

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Hypothalamus (continued)
prolactin, s135
subcellular LHRH particles, 301
sucrose density gradient fractionation, 301
supraoptic nucleus, s27
ultrastructural cytology, 37
vasopressin, s239
Hypothermia
d-amphetamine, 179
anterior hypothalamus, 333
drug interaction, 179
β-endorphin, 179
morphine, 179
motor activity, 179
naloxone, 179
neurotensin, 333
peptide, 179
periaqueductal gray, 333
preoptic area, 333

Immunochemistry
distribution, 159
endocrine, 159
neurotensin, 159
peptide, 159
radioimmunoassay, 159
Immunocytochemistry
ACTH, s3, s11
aging, s239
anatomy, 23
axosomatic synapses, 37
brain, 23
catecholamines, 77
cell culture, s211
congenital deficiency, 11
development, 315
development of somatostatin neurons, s79
dynorphin, s11
β-endorphin, s3, s11, 23
enkephalin, 23
extrahypothalamic innervation, 315
fetus, 315
histofluorescence, 77
hypothalamus, 37, s211, s239
LHRH, 37
α-MSH, s11, 23
neural grafts, 11
neuroanatomy, s3, s11
neuronal cell markers, s211
neuropeptides, s3
neurophysin, s3, 11, 77, s239
noradrenaline, 23
ontogeny, 77
opiate peptides, s11
oxytocin, s3, s239, 315
paraventricular nucleus, 77, 315
supraoptic nucleus, 77, 315
ultrastructural cytology, 37
vasopressin, s3, 11, 77, s239, 315
Immunohistochemistry
ACTH, 249
adrenal cortex, 249
direct interaction of peptide regulators and target cell nuclei, 249
prolactin, 249
In vitro prolactin release
prolactin, 325
vasoactive intestinal peptide, 325

Incentive motivation
drinking, 353
dynorphin, 353
[D-Ala^2,F$_5$Phe^4]-Met-enkephalin-NH$_2$, 353
[D-Phe^4]-Met-enkephalin, 353
MIF-I, 353
naloxone, 353
Insulin
β-endorphin, 309
naltrexone, 309
obesity, 309
opiate peptides, 309
pancreatic islets, 309
pituitary, 309
Interspecies conservation
variation in peptidergic neurons, s21
Interspecies variation
peptidergic neurons, s21
Intestinal
endocrine, 167
neurotensin, 167
peptide, 167
radioimmunoassay, 167
sequence, 167
Invertebrates
anatomical distribution, 211
Met-enkephalin, 211
Met-enkephalin sulphoxide, 211
phylogenetic distribution, 211
radioimmunoassay, 211
vertebrates, 211
Isovaleroyl chloride
mixed anhydride coupling, 187
peptide formylation, 187

Learning
ACTH, 277
activity, 365
analgesia, 365
attention, 277
dynorphin, 365
endorphin, 365
enkephalin, 365
hormones, 365
localization, 365
memory, 365
MSH, 277
neurotransmitters, 365
peptides, 277
receptors, 365
schizophrenia, 365
tolerance, 365
LH
bradykinin, 201
FSH, 201
GH, 201
prolactin, 201
TSH, 201
LHRH
androgenized females, s85
anovulatory syndrome, s85
axosomatic synapses, 37
estrogen, 301
hypothalamic-pituitary axis, s85
hypothalamus, 37, 301
immunocytochemistry, 37
median eminence, 97
organum vasculosum lamina terminalis, 97

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

subcellular LHRH particles, 301
sucrose density gradient fractionation, 301
ultrastructural cytology, 37
Light
exophthalmia, 19
Harderian gland, 19
α-MSH, 19
photoperiod, 19
photoreceptor, 19
pituitary, 19
retina, 19
Localization
activity, 365
analgesia, 365
dynorphin, 365
endorphin, 365
enkephalin, 365
hormones, 365
learning, 365
memory, 365
neurotransmitters, 365
receptors, 365
schizophrenia, 365
tolerance, 365
Locomotor activity
ambient temperature, 243
amphetamine, 243
catalepsy, 103
chlorpromazine, 243
drug interaction, 243
FLA-63, 103
haloperidol, 103
α-methylparatyrosine, 103
MIF-I, 243
α-MSH, 243
muscular rigidity, 103
neuropeptides, 103
phenoxybenzamine, 103
substance P, 103
thermoregulation, 243

Maturation
supraoptic nucleus, s51
Meal size
cerebral ventricular injections, 51
cholecystokinin-octapeptide, 51
cumulative daily feed intake, 51
eating, 51
sheep, 51
Median eminence
dopamine, 59
gonadotropin-releasing hormone, 59
LHRH, 97
organum vasculosum lamina terminalis, 97
simultaneous histofluorescence-immunocytochemistry, 59
Melatonin
aging, s69
defecation, 147
emotionality, 147
enkephalin, 73
11-hydroxycorticosterone, 147
hypophysectomy, 147
hypothalamic ovary, s69
memory, 147
MSH, 73
α-MSH, 147
naloxone, 73
narcolepsy, 281
passive avoidance, 147
pineal gland, s69, 281
REM sleep, 281
reproductive gonadotrophin, s69
vasotocin, 281
xanthophore aggregation, 73
Memory
activity, 365
aging, s197
analgesia, 365
defecation, 147
dynorphin, 365
emotionality, 147
endorphin, 365
enkephalin, 365
hormones, 365
11-hydroxycorticosterone, 147
hypophysectomy, 147
learning, 365
localization, 365
melatonin, 147
α-MSH, 147
neurotransmitters, 365
opiate receptors, s197
passive avoidance, 147
receptors, 365
schizophrenia, 365
tolerance, 365
Mental retardation
ACTH/MSH$_{4-9}$ analog, 109
awareness enhancement, 109
Method
autoradiography, s79
immunochemistry, 159
immunocytochemistry, s3, 11, s11, s21, 23, 37, 77, s79, s211, s239, 315
immunohistochemistry, 249
peptide formylation, 187
radioimmunoassay, s51, 159, 167, 211, 257
simultaneous histofluorescence-immunochemistry, 59
sucrose density gradient fractionation, 301
α-Methylparatyrosine
catalepsy, 103
FLA-63, 103
haloperidol, 103
locomotor activity, 103
muscular rigidity, 103
neuropeptides, 103
phenoxybenzamine, 103
substance P, 103
3-Methyl-tyrosine
alpha-methyl-tyrosine, 175
3-fluoro-tyrosine, 175
Met-enkephalin, 175
opiates, 175
peptide, 175
tetrafluorotyrosine, 175
tyrosine-modified analogs, 175
vas deferens, 175
MIF-I
ambient temperature, 243
amphetamine, 243
analgesia, 293
chlorpromazine, 243
drinking, 353
drug interaction, 243
dynorphin, 353
[D-Ala^2,F$_5$Phe^4]-Met enkephalin-NH$_2$, 353
[D-Phe^4]-Met-enkephalin, 353

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

MIF-I (continued)
guinea pig ileum, 293
incentive motivation, 353
locomotion, 243
morphine, 293
motor activity, 293
mouse vas deferens, 293
α-MSH, 243
naloxone, 353
opiate receptors, 293
thermoregulation, 243
Mixed anhydride coupling
isovaleroyl chloride, 187
peptide formylation, 187
Monoamines
aging, s141
neuronal interactions, s141
neuropeptides, s141
supraoptic nucleus, s141
Morphine
d-amphetamine, 179
analgesia, 293
drug interaction, 179
β-endorphin, 179
enkephalin, 237
guinea pig ileum, 293
hypothermia, 179
MIF-I, 293
motor activity, 179, 293
mouse vas deferens, 293
naloxone, 179, 237
opiate receptors, 293
peptide, 179
pupil mydriasis, 237
Motilin
activity, 383
drinking, 383
eating, 383
gastrin, 383
vasoactive intestinal polypeptide, 383
Motor activity
d-amphetamine, 179
analgesia, 293
drug interaction, 179
β-endorphin, 179
guinea pig ileum, 293
hypothermia, 179
MIF-I, 293
morphine, 179, 293
mouse vas deferens, 293
naloxone, 179
opiate receptors, 293
peptide, 179
Motor endplates
ACTH, 135
axon length, 135
crush denervation, 135
motor function, 135
muscle fibers, 135
protein synthesis, 135
regeneration, 135
sensation, 135
Motor function
ACTH, 135
axon length, 135
crush denervation, 135
motor endplates, 135
muscle fibers, 135
protein synthesis, 135
regeneration, 135
sensation, 135
Mouse vas deferens
analgesia, 293
guinea pig ileum, 293
MIF-I, 293
morphine, 293
motor activity, 293
opiate receptors, 293
MSH
ACTH, 15, 55, 277
aggression, 69
aging, 55
ambient temperature, 243
amphetamine, 243
anatomy, 23
attention, 55, 277
birth, 125
body temperature, 15
brain, 23, 125
central peptides, 15
chlorpromazine, 243
cognition, 55
defecation, 147
drug interaction, 243
emotionality, 147
β-endorphin, 23
enkephalin, 23, 73
exophthalmia, 19
glucagon, 15
Harderian gland, 19
human, 55
11-hydroxycorticosterone, 147
hypophysectomy, 147
immunocytochemistry, s11
learning, 277
light, 19
locomotion, 243
melatonin, 73, 147
memory, 147
MIF-I, 243
naloxone, 73
neuroanatomy, s11, 23
noradrenaline, 23
olfaction, 69
opiate peptides, s11
oxytocin, 15
passive avoidance, 147
peptide, 55, 277
photoperiod, 19
photoreceptor, 19
pituitary, 19, 125
plasma, 125
preputial gland, 69
retina, 19
sexual maturity, 125
thermoregulation, 243
vasopressin, 15
visual retention, 55
xanthophore aggregation, 73
Muscle fibers
ACTH, 135
axon length, 135
crush denervation, 135
motor endplates, 135
motor function, 135
protein synthesis, 135
regeneration, 135
sensation, 135

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Muscular rigidity
catalepsy, 103
FLA-63, 103
haloperidol, 103
locomotor activity, 103
α-methylparatyrosine, 103
neuropeptides, 103
phenoxybenzamine, 103
substance P, 103

Naloxone
d-amphetamine, 179
analgesia, 341
drinking, 353
drug interaction, 179
dynorphin, 341, 353
eating, 341
β-endorphin, 179
enkephalin, 73, 237
[D-Ala^2,F$_5$Phe^4]-Met-enkephalin-NH$_2$, 353
[D-Phe^4]-Met-enkephalin, 353
grooming, 341
hypothermia, 179
incentive motivation, 353
melatonin, 73
MIF-I, 353
morphine, 179, 237
motor activity, 179
MSH, 73
opioid, 341
peptide, 179
pupil mydriasis, 237
rearing, 341
xanthophore aggregation, 73
Naltrexone
β-endorphin, 309
insulin, 309
obesity, 309
opiate peptides, 309
pancreatic islets, 309
pituitary, 309
Narcolepsy
melatonin, 281
pineal gland, 281
REM sleep, 281
vasotocin, 281
Neural grafts
congenital deficiency, 11
immunocytochemistry, 11
neurophysin, 11
vasopressin, 11
Neural transplantation
arrest and migration of cerebellar neurons, s221
autonomic ganglia, s221
neurotrophism, s221
Neuroanatomy
ACTH, s3, s11
dynorphin, s11
β-endorphin, s3, s11
immunocytochemistry, s3, s11
α-MSH, s11
neuropeptides, s3
neurophysin, s3
opiate peptide, s11
oxytocin, s3
vasopressin, s3

Neurohypophyseal function
aging, s159
baroregulation, s159
osmoregulation, s159
vasopressin, s159
Neurohypophysis
fetal development, s45
neurophysins, s45
oxytocin, s45
vasopressin, s45
Neuronal cell markers
cell culture, s211
hypothalamus, s211
immunocytochemistry, s211
Neuronal interactions
aging, s141
monoamines, s141
neuropeptides, s141
supraoptic nucleus, s141
Neuropeptides
ACTH, s3
aging, s141
catalepsy, 103
β-endorphin, s3
FLA-63, 103
haloperidol, 103
immunocytochemistry, s3
locomotor activity, 103
α-methylparatyrosine, 103
monoamines, s141
muscular rigidity, 103
neuroanatomy, s3
neuronal interactions, s141
neurophysin, s3
oxytocin, s3
phenoxybenzamine, 103
substance P, 103
supraoptic nucleus, s141
vasopressin, s3
Neurophysin
aging, s239
catecholamines, 77
congenital deficiency, 11
fetal development, s45
histofluorescence, 77
hormonal effects on transplanted embryonic hypothalamus, s117
hypothalamus, s27, s239
immunocytochemistry, s3, 11, 77, s239
neural grafts, 11
neuroanatomy, s3
neurohypophysis, s45
neuropeptides, s3
ontogeny, s27, 77
oxytocin, s45, s239
paraventricular nucleus, 77
supraoptic nucleus, s27, 77
vasopressin, 11, 77
Neurotensin
anterior hypothalamus, 333
bombesin, 381
bPTH$_{1-34}$, 285
bradykinin, 285
cholesterol, 381
corticotropin inhibiting peptide, 285
distribution, 159
duration of action, 285
effectiveness, 285
eledoisin, 285
endocrine, 159, 167

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Neurotensin (continued)
hypothermia, 333
immunochemistry, 159
intestinal, 167
peptide, 159, 167
periaqueductal gray, 333
potency, 285
preoptic area, 333
radioimmunoassay, 159, 167
sequence, 167
somatostatin, 381
substance P, 285, 381
vasoactive intestinal peptide, 285
xenopsin, 285
Neurotransmitters
activity, 365
analgesia, 365
dynorphin, 365
endorphin, 365
enkephalin, 365
hormones, 365
learning, 365
localization, 365
memory, 365
receptors, 365
schizophrenia, 365
tolerance, 365
Neurotrophism
arrest and migration of cerebellar neurons, s211
autonomic ganglia, s211
neural transplantation, s211
Nigral transplants
caudate nucleus, s111
functional reinnervation, s111
6-hydroxydopamine, s111
regeneration, s111
substantia nigra, s111
Nigro-striatal system
functional aging, s177
Nodose ganglia
aortic nerve, 359
baroreceptors, 359
chemoreceptors, 359
retrograde transport, 359
substance P, 359
'true blue', 359
Noradrenaline
anatomy, 23
brain, 23
β-endorphin, 23
enkephalin, 23
immunocytochemistry, 23
α-MSH, 23
Noradrenergic feeding "circuit"
cholecystokinin, 47
eating, 47
hypothalamic feeding, 47
norepinephrine, 47
satiety mechanism, 47
Norepinephrine
cholecystokinin, 47
eating, 47
hypothalamic feeding, 47
noradrenergic feeding "circuit", 47
satiety mechanism, 47
Nucleus tractus solitarius
aortic arch afferents, 1
baroreceptors, 1
chemoreceptors, 1
substance P, 1
vagal afferents, 1

Obesity
β-endorphin, 309
insulin, 309
naltrexone, 309
opiate peptides, 309
pancreatic islets, 309
pituitary, 309
Olfaction
aggression, 69
α-MSH, 69
preputial gland, 69
Ontogeny
catecholamines, 77
histofluorescence, 77
hypothalamus, s27
immunocytochemistry, 77
neurophysin, s27, 77
paraventricular nucleus, 77
supraoptic nucleus, s27, s51, 77
vasopressin, 77
Opiate peptides
ACTH, s11
dynorphin, s11
β-endorphin, s11, 309
immunocytochemistry, s11
insulin, 309
α-MSH, s11
naltrexone, 309
neuroanatomy, s11
obesity, 309
pancreatic islets, 309
pituitary, 309
Opiate receptors
aging, s197
analgesia, 293
guinea pig ileum, 293
memory, s197
MIF-I, 293
morphine, 293
motor activity, 293
mouse vas deferens, 293
Opiates
alpha-methyl-tyrosine, 175
3-fluoro-tyrosine, 175
Met-enkephalin, 175
3-methyl-tyrosine, 175
peptide, 175
tetrafluorotyrosine, 175
tyrosine-modified analogs, 175
vas deferens, 175
Opioid
analgesia, 341
dynorphin, 341
eating, 341
grooming, 341
naloxone, 341
rearing, 341
Organum vasculosum lamina terminalis
LHRH, 97
median eminence, 97
Osmoregulation
aging, s159
neurohypophyseal function, s159

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Ovarian-hypothalamic-pituitary
aging, s163
interaction, s163
reproduction, s163
Oxytocin
ACTH, 15
aging, s239
body temperature, 15
central peptides, 15
development, 315
extrahypothalamic innervation, 315
fetal development, s45
fetus, 315
glucagon, 15
hypothalamus, s239
immunocytochemistry, s3, s239, 315
α-MSH, 15
neuroanatomy, s3
neurohypophysis, s45
neuropeptides, s3
neurophysin, s45, s239
paraventricular nucleus, 315
supraoptic nucleus, 315
vasopressin, 15, s45, s239, 315

Pancreatic diversion
duodenal pH, 155
pancreatic secretion, 155
secretin, 155
Pancreatic islets
β-endorphin, 309
insulin, 309
naltrexone, 309
obesity, 309
opiate peptides, 309
pituitary, 309
Pancreatic secretion
duodenal pH, 155
pancreatic diversion, 155
secretin, 155
Paraventricular nucleus
catecholamines, 77
development, 315
extrahypothalamic innervation, 315
fetus, 315
histofluorescence, 77
immunocytochemistry, 77, 315
neurophysin, 77
ontogeny, 77
oxytocin, 315
supraoptic nucleus, 77, 315
vasopressin, 77, 315
Passive avoidance
defecation, 147
emotionality, 147
11-hydroxycorticosterone, 147
hypophysectomy, 147
melatonin, 147
memory, 147
α-MSH, 147
Peptide
ACTH, 55, 277
aging, 55
alpha-methyl-tyrosine, 175
d-amphetamine, 179
attention, 55, 277
blood-brain barrier, 347
bombesin, 347
cholecystokinin, 347
cognition, 55
CSF, 347
distribution, 159
drug interaction, 179
endocrine, 159, 167
β-endorphin, 179
Met-enkephalin, 175
3-fluoro-tyrosine, 175
human, 55
hypothermia, 179
immunochemistry, 159
intestinal, 167
learning, 277
3-methyl-tyrosine, 175
morphine, 179
motor activity, 179
MSH, 55, 277
naloxone, 179
neurotensin, 159, 167
opiates, 175
radioimmunoassay, 159, 167
relationship, 347
sequence, 167
tetrafluorotyrosine, 175
tyrosine-modified analogs, 175
vas deferens, 175
visual retention, 55
Peptide formylation
isovaleroyl chloride, 187
mixed anhydride coupling, 187
Peptidergic neurons
functional development, s125
interspecies conservation and variation, s21
transplants, s125
Periaqueductal gray
anterior hypothalamus, 333
hypothermia, 333
neurotensin, 333
preoptic area, 333
Phenoxybenzamine
catalepsy, 103
FLA-63, 103
haloperidol, 103
locomotor activity, 103
α-methylparatyrosine, 103
muscular rigidity, 103
neuropeptides, 103
substance P, 103
Photoperiod
exophthalmia, 19
Harderian gland, 19
light, 19
α-MSH, 19
photoreceptor, 19
pituitary, 19
retina, 19
Photoreceptor
exophthalmia, 19
Harderian gland, 19
light, 19
α-MSH, 19
photoperiod, 19
pituitary, 19
retina, 19
Phylogenetic distribution
anatomical distribution, 211
Met-enkephalin, 211
Met-enkephalin sulphoxide, 211
invertebrates, 211

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Phylogenetic distribution (continued)
radioimmunoassay, 211
vertebrates, 211
Pineal gland
aging effects, s69
hypothalamic ovary, s69
melatonin, s69, 281
narcolepsy, 281
REM sleep, 281
reproductive gonadotrophins, s69
vasotocin, 281
Pituitary
birth, 125
brain, 125
β-endorphin, 309
exophthalmia, 19
Harderian gland, 19
insulin, 309
light, 19
α-MSH, 19, 125
naltrexone, 309
obesity, 309
opiate peptides, 309
pancreatic islets, 309
photoperiod, 19
photoreceptor, 19
plasma, 125
retina, 19
sexual maturity, 125
Plasma
birth, 125
brain, 125
α-MSH, 125
pituitary, 125
sexual maturity, 125
Plasma corticosterone
$ACTH_{4-10}$, 207
conditioned taste aversion, 207
Postnatal
prenatal, s229
supraoptic nucleus, s229
synaptogenesis, s229
Potency
$bPTH_{1-34}$, 285
bradykinin, 285
corticotropin inhibiting peptide, 285
duration of action, 285
effectiveness, 285
eledoisin, 285
neurotensin, 285
substance P, 285
vasoactive intestinal peptide, 285
xenopsin, 285
Prenatal
postnatal, s229
supraoptic nucleus, s229
synaptogenesis, s229
Preoptic area
anterior hypothalamus, 333
hypothermia, 333
neurotensin, 333
periaqueductal gray, 333
Preputial gland
aggression, 69
α-MSH, 69
olfaction, 69
Progestin
hormonal effects on transplanted embryonic hypothalamus, s117
Prolactin
ACTH, 249
adrenal cortex, 249
aging, s135
bradykinin, 201
direct interaction of peptide regulators and target cell nuclei, 249
dopamine, s135
FSH, 201
GH, 201
hypophyseal secretion, s135
hypothalamus, s135
immunohistochemistry, 249
in vitro prolactin release, 325
LH, 201
TSH, 201
vasoactive intestinal peptide, 325
Protein synthesis
ACTH, 135
axon length, 135
crush denervation, 135
motor endplates, 135
motor function, 135
muscle fibers, 135
regeneration, 135
sensation, 135
Pupil mydriasis
enkephalin, 237
morphine, 237
naloxone, 237

Rabbit neutrophils
antagonists, 289
chemotaxis, 289
formyl-Met-Leu-Phe-OH, 289
rapid mixed anhydride coupling, 289
Radioimmunoassay
acromegaly, 257
anatomical distribution, 211
distribution, 159
endocrine, 159, 167
Met-enkephalin, 211
Met-enkephalin sulphoxide, 211
half-life, 257
hepatic failure, 257
immunochemistry, 159
intestinal, 167
invertebrates, 211
neurotensin, 159, 167
peptide, 159, 167
phylogenetic distribution, 211
sequence, 167
somatostatin, 257
supraoptic nucleus, s51
vertebrates, 211
Rapid mixed anhydride coupling
antagonists, 289
chemotaxis, 289
formyl-Met-Leu-Phe-OH, 289
rabbit neutrophils, 289
Rearing
analgesia, 341
dynorphin, 341
eating, 341
grooming, 341
naloxone, 341
opioid, 341

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Receptors
activity, 365
analgesia, 365
dynorphin, 365
endorphin, 365
enkephalin, 365
hormones, 365
learning, 365
localization, 365
memory, 365
neurotransmitters, 365
schizophrenia, 365
tolerance, 365
Regeneration
ACTH, 135
axon length, 135
crush denervation, 135
functional reinnervation, s111
motor endplates, 135
motor function, 135
muscle fibers, 135
nigral transplants, s111
protein synthesis, 135
sensation, 135
Relationship
blood-brain barrier, 347
bombesin, 347
cholecystokinin, 347
CSF, 347
peptide, 347
REM sleep
melatonin, 281
narcolepsy, 281
pineal gland, 281
vasotocin, 281
Reproduction
aging, s163
ovarian-hypothalamic-pituitary interaction, s163
Reproductive gonadotrophin
aging, s69
hypothalamic ovary, s69
melatonin, s69
pineal gland, s69
Retina
exophthalmia, 19
Harderian gland, 19
light, 19
α-MSH, 19
photoperiod, 19
photoreceptor, 19
pituitary, 19
Retrograde transport
aortic nerve, 359
baroreceptors, 359
chemoreceptors, 359
nodose ganglia, 359
substance P, 359
'true blue', 359
Rheumatoid arthritis
acrophase, 387
$ACTH_{1-17}$, 387
circadian, 387
cosinor analysis, 387
urinary free cortisol, 387

Satiety
behavioral sequence of satiety, 131
bombesin, 131
eating, 131
gastric cannula, 131
sham feeding, 131
Satiety mechanism
cholecystokinin, 47
eating, 47
hypothalamic feeding, 47
noradrenergic feeding "circuit", 47
norepinephrine, 47
Schizophrenia
activity, 365
analgesia, 365
dynorphin, 365
endorphin, 365
enkephalin, 365
hormones, 365
learning, 365
localization, 365
memory, 365
neurotransmitters, 365
receptors, 365
tolerance, 365
Secretin
duodenal pH, 155
pancreatic diversion, 155
pancreatic secretion, 155
Sensation
ACTH, 135
axon length, 135
crush denervation, 135
motor endplates, 135
motor function, 135
muscle fibers, 135
protein synthesis, 135
regeneration, 135

Sequence
endocrine, 167
intestinal, 167
neurotensin, 167
peptide, 167
radioimmunoassay, 167
Sexual maturity
birth, 125
brain, 125
α-MSH, 125
pituitary, 125
plasma, 125
Sham feeding
behavioral sequence of satiety, 131
bombesin, 131
eating, 131
gastric cannula, 131
satiety, 131
Sheep
cerebral ventricular injections, 51
cholecystokinin-octapeptide, 51
cumulative daily feed intake, 51
eating, 51
meal size, 51
Short-term memory
spatial memory, 261
vasopressin analogues, 261
Simultaneous histofluorescence-immunochemistry
dopamine, 59
gonadotropin-releasing hormone, 59
median eminence, 59

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

Somatostatin
acromegaly, 257
autoradiography, s79
bombesin, 381
cholesterol, 381
development, s79
half-life, 257
hepatic failure, 257
immunocytochemistry, s79
neurotensin, 381
radioimmunoassay, 257
substance P, 381
Spatial memory
short-term memory, 261
vasopressin analogues, 261
Steroidogenesis
ACTH, 223
endorphin, 223
guinea pig, 223
Subcellular LHRH particles
estrogen, 301
hypothalamus, 301
LHRH, 301
sucrose density gradient fractionation, 301
Substance P
aortic arch afferents, 1
aortic nerve, 359
baroreceptors, 1, 359
bombesin, 381
$bPTH_{1-34}$, 285
bradykinin, 285
catalepsy, 103
chemoreceptors, 1, 359
cholesterol, 381
corticotropin inhibiting peptide, 285
duration of action, 285
effectiveness, 285
eledoisin, 285
FLA-63, 103
haloperidol, 103
locomotor activity, 103
α-methylparatyrosine, 103
muscular rigidity, 103
neuropeptides, 103
neurotensin, 285, 381
nodose ganglia, 359
nucleus tractus solitarius, 1
phenoxybenzamine, 103
potency, 285
retrograde transport, 359
somatostatin, 381
'true blue', 359
vagal afferents, 1
vasoactive intestinal peptide, 285
xenopsin, 285
Substantia nigra
functional brain transplants, s101
functional reinnervation, s111
nigral transplants, s111
Sucrose density gradient fractionation
estrogen, 301
hypothalamus, 301
LHRH, 301
subcellular LHRH particles, 301
Supraoptic nucleus
aging, s141
catecholamines, 77
cytodifferentiation, s51
development, 315
extrahypothalamic innervation, 315
fetus, 315
histofluorescence, 77
hypothalamus, s27
immunocytochemistry, 77, 315
maturation, s51
monoamine, s141
neuronal interactions, s141
neuropeptides, s141
neurophysin, s27, 77
ontogeny, s27, s51, 77
oxytocin, 315
paraventricular nucleus, 77, 315
postnatal, s229
prenatal, s229
radioimmunoassay, s51
synaptogenesis, s229
ultrastructural evaluation, s51
vasopressin, 77, 315
Synaptogenesis
postnatal, s229
prenatal, s229
supraoptic nucleus, s229

Taurine
akinesia, 139
γ-aminobutyric acid, 139
analgesia, 139
D-Ala^2-Met-enkephalinamide, 139
Tetrafluorotyrosine
alpha-methyl-tyrosine, 175
3-fluoro-tyrosine, 175
Met-enkephalin, 175
3-methyl-tyrosine, 175
opiates, 175
peptide, 175
tyrosine-modified analogs, 175
vas deferens, 175
Theoretical implications
aging, s185
brain, s185
endocrine system, s185
Thermoregulation
ambient temperature, 243
amphetamine, 243
chlorpromazine, 243
drug interaction, 243
locomotion, 243
MIF-I, 243
α-MSH, 243
Tolerance
activity, 365
analgesia, 365
dynorphin, 365
endorphin, 365
enkephalin, 365
hormones, 365
learning, 365
localization, 365
memory, 365
neurotransmitters, 365
receptors, 365
schizophrenia, 365
Transplanted embryonic hypothalamus
development, s117
estrogen, s117
hormonal effects, s117
neurophysin, s117
progestin, s117

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV* . . . Suppl., Vol. 1, 1980.

Transplants
functional development, s125
peptidergic neurons, s125
'True blue'
aortic nerve, 359
baroreceptors, 359
chemoreceptors, 359
nodose ganglia, 359
retrograde transport, 359
substance P, 359
TSH
bradykinin, 201
FSH, 201
GH, 201
LH, 201
prolactin, 201
Tyrosine-modified analogs
alpha-methyl-tyrosine, 175
3-fluoro-tyrosine, 175
Met-enkephalin, 175
3-methyl-tyrosine, 175
opiates, 175
peptide, 175
tetrafluorotyrosine, 175
vas deferens, 175

Ultrastructural cytology
axosomatic synapses, 37
hypothalamus, 37
immunocytochemistry, 37
LHRH, 37
Ultrastructural evaluation
supraoptic nucleus, s51
Urinary free cortisol
acrophase, 387
$ACTH_{1-17}$, 387
circadian, 387
cosinor analysis, 387
rheumatoid arthritis, 387

Vagal afferents
aortic arch afferents, 1
baroreceptors, 1
chemoreceptors, 1
nucleus tractus solitarius, 1
substance P, 1
Vas deferens
alpha-methyl-tyrosine, 175
3-fluoro-tyrosine, 175
Met-enkephalin, 175
3-methyl-tyrosine, 175
opiates, 175
peptide, 175
tetrafluorotyrosine, 175
tyrosine-modified analogs, 175
Vasoactive intestinal peptide
$bPTH_{1-34}$, 285
bradykinin, 285
corticotropin inhibiting peptide, 285
duration of illness, 285
effectiveness, 285
eledoisin, 285
in vitro prolactin release, 325
neurotensin, 285
potency, 285
prolactin, 325
substance P, 285
xenopsin, 285
Vasoactive intestinal polypeptide
activity, 383
drinking, 383
eating, 383
gastrin, 383
motilin, 383
Vasopressin
ACTH, 15
aging, s159, s239
body temperature, 15
brain development, s203
catecholamines, 77
central peptides, 15
congenital deficiency, 11
development, 315
extrahypothalamic innervation, 315
fetal development, s45
fetus, 315
glucagon, 15
histofluorescence, 77
hypothalamus, s239
immunocytochemistry, s3, s11, 77, s239, 315
α-MSH, 15
neural grafts, 11
neuroanatomy, s3
neurohypophyseal function, s159
neurohypophysis, s45
neuropeptides, s3
neurophysin, 11, s45, 77, s239
ontogeny, 77
oxytocin, 15, s45, s239, 315
paraventricular nucleus, 77
supraoptic nucleus, 77, 315
Vasopressin analogues
short-term memory, 261
spatial memory, 261
Vasotocin
melatonin, 281
narcolepsy, 281
pineal gland, 281
REM sleep, 281
Vertebrates
anatomical distribution, 211
Met-enkephalin, 211
Met-enkephalin sulphoxide, 211
invertebrates, 211
phylogenetic distribution, 211
radioimmunoassay, 211
Visual retention
ACTH, 55
aging, 55
attention, 55
cognition, 55
human, 55
MSH, 55
peptide, 55
Xanthophore aggregation
enkephalin, 73
melatonin, 73
MSH, 73
naloxone, 73
Xenopsin
$bPTH_{1-34}$, 285
bradykinin, 285
corticotropin inhibiting peptide, 285
duration of illness, 285
effectiveness, 285
eledoisin, 285
neurotensin, 285
potency, 285
substance P, 285
vasoactive intestinal peptide, 285

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

AUTHOR INDEX

AKIL, H., s11, 31, 341
ADLER, M. W., 237
ARIMURA, A. A., s85, 257

BAILE, C. A., 51
BACINO, C. B., 333
BANKS, W. A., 347
BARBEAU, A., 103, 139
BARCHAS, J. D., 23, 31
BELANGER, F., 103
BECKWITH, B. E., 277
BERZAS, M. C., 353
BHATNAGAR, Y. M., 159, 167
BJÖRKLUND, A., s111, s117
BLACKER, D., 31
BOER, G. J., s203
BOPP, M. J., 55
BRIGHTMAN, M. W., s221
BUIJS, R. M., s203, 315
BUREŠOVÁ, O., 261

CARRAWAY, R., 159, 167
CELIS, M. E., 125
CHANG, J. K., 285
CHANG, T. M., 155
CHEY, W. Y., 155
CHOY, V. J., s239
CHU, L., 37
CIARANELLO, R. D., 23
CLARK, J. H., 301
COWAN, A., 237
COY, D. H., 175, 179, 257, 353, 365, 383
CZERNICHOW, P., s45

DATTA, P. C., 147
DAY, A. R., 187, 289
DE LANEROLLE, N., s21
DELLA-FERA, M. A., 51
DELLMANN, H.-D., s229
DE VRIES, G. J., s203
DICK, L. B., s79
DICKINSON, S. L., 293
DUNNETT, S. B., s111

ELDE, R., s21
ELDRIDGE, J. C., s185

FAWCETT, C. P., 97
FELICIO, L. S., s163
FINCH, C. E., s163
FISHBACK, J., 257
FISHER, C., 125
FLURKEY, K., s163
FOREMAN, M. M., s135
FOURIEZOS, G., 103
FREER, R. J., 187, 289

GADDE, C. A., s27
GARDNER, C. F., 381
GASH, D. M., 11, s51, s79, s125
GASSON, J. C., 223
GEE, D. M., s163
GIBBS, J., 131
GLYN, J. R., 15
GOLDMAN, W., 359
GOLDSTEIN, R., s27, 281
GONZALEZ-BARCENA, D., 257
GROVES, G. A., 55
GUDELSKY, G. A., s135
GÜNTHER, R., 387

HABER, S., s21
HALBERG, E., 387
HALBERG, E., 387
HALBERG, F., 387
HELKE, C. J., 1, 359
HEROLD, M., 387
HIRSCHOWITZ, B. I., 217
HO, R., s21
HOFFMAN, D. L., s3
HOFFMAN, G. E., s79, s141
HOLETS, V., s21
HOSTETTER, G., 37

IBANEZ, M. L., 353
IZUMI, K., 139

JACOBOWITZ, D. M., 1, 359
JAFFE, R., s211
JENSEN, R. A., s197
JOHNSON, L. Y., s69
JOLICOEUR, F. B., 103

KASTIN, A. J., 19, 55, 175, 179, 243, 257, 277, 353, 365, 383
KATZ, R. J., 341
KERDELHUÉ, B., 37
KHACHATURIAN, H., s51, 77, s141
KIM, Y. C., 155
KING, B. M., 353
KING, J. A., 211
KING, J. C., s85
KING, M. G., 147
KOZLOWSKI, G. P., 37
KRUPP, L., s3
KUNG, T. T., 135

LANDFIELD, P. W., s185
LAWTON, C. A., 109
LEE, K. Y., 155
LEVINE, S., 207
LIPTON, J. M., 15
LOWE, I. P., s211
LUCIANO, M., 309

McCALEB, M. L., 47
McCANN, S. M., 97, 201, 325
McEWEN, B. S., s117
McGAUGH, J. L., s197
McKELVY, J. F., s211
McNEILL, T. H., 59

MALEY, B., s21
MARTIN, C. F., 131
MARTIN, G. E., 333
MARTINEZ, J. L., JR., s197
MATTHEW, E., s3
MESSING, R. B., s197
MICEVYCH, P., s21
MILLAR, R. P., 211
MILLER, L. H., 55
MILLIKAN, L., 155
MOBBS, C., s163
MORRIS, M., s185
MUNEKATA, E., 139
MUTHUKUMARASWAMY, N., 187, 289
MYERS, R. D., 47

NAKANISHI, T., 139
NANSEL, D. D., s135
NEGRO-VILAR, A., 201
NELSON, J. F., s163
NILAVER, G., s3
NISHIWAKI, H., 155
NOLIN, J. M., 249
NOWELL, N. W., 69

O'DONOHUE, T. L., 1
OLSON, G. A., 353, 365, 383
OLSON, R. D., 353, 365, 383
O'STEEN, W. K., 19
OSTERBURG, H. H., s163

PADEN, C. M., s117
PANG, P. K. T., 285
PAPP, N. L., 333
PAVEL, S., 281
PECK, E. J., JR., 301
PERIC-GOLIA, L., 381
PERIC-GOLIA, M., 381
PERLOW, M. J., s101
PERT, C. B., 309
PETRESCU, M., 281
PETTERBORG, L. J., s69
PILOTTE, N. S., s135
PINON, D., 289
PORTER, J. C., s135

RANDALL, P. K., s177
RECANT, L., 309
REITER, R. J., s69
REYMOND, M. J., s135
RICHARD, C. W., III, 23
RICHARDSON, B. A., 69
ROBERTSON, G. L., s159
ROBINSON, A. G., s45
RONDEAU, D. B., 103
ROSENSTEIN, J. M., s221
ROWE, J., s159

SAID, S. I., 325
SAMSON, W. K., 97, 325
SANDMAN, C. A., 109, 277
SATAKE, N., 73
SCHALLY, A. V., 257
SCHIMIZU, M., 285
SCHÖLER, J., s141
SCOTT, D. E., s1, s51, 59, s247
SEIF, S. M., s45
SEYBOLD, V., s21
SIKORA, K. C., s229
SILVERMAN, A-J, s27, s117
SINDING, C., s45

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.

ŠKOPKOVÁ, J., 261
SLADEK, C. D., s51, s125
SLADEK, J. R., JR., s1, 11, s51, 59, 77, s125, s141
SLATER, P., 293
SMITH, M. S., s185
SMOTHERMAN, W. P., 207
SNAVELY, F. L., s85
SNYDER, G., 97, 327
SPIEHLER, V. R., s197
STEELE, M. K., 201
STEGER, R. W., s69
STENEVI, U., s111, s117
STEWART, J. M., 231
STRAND, F. L., 135
SULLIVAN, S., 31
SUNDBERG, D. K., s185
SWAAB, D. F., s203, 315

TENNER, T. E., JR., 285
TORTELLA, F. C., 237
THODY, A. J., 69, 125
THORNGREN, K. G., s117
TILDERS, F. J. H., s135
TOBET, S. A., s85
TYTELL, M., 301

VASQUEZ, B. J., s197
VAVREK, R. J., 231
VELIS, D. N., 315
VON ALMEN, T. K., 353, 383
VOYLES, N. R., 309

WALKER, B. B., 109
WALKER, J. M., s11, 341
WATKINS, W. B., s239
WATSON, S. J., s11, 23
WOODLEY, R., 69

YAMAMOTO, H., 139
YANG, C. M., 285
YEHUDA, S., 179, 243
YUNIS, E. J., s211

ZADINA, J., 179
ZIMMERMAN, E. A., s3

Numbers preceded by the letter "s" indicate items appearing in *Brain-Endocrine Interaction Symposium IV . . .* Suppl., Vol. 1, 1980.